Cancer screening technology developer BioView Ltd. (TASE:BIOV) said today that it had completed the sale of another scanning system, including specially developed algorithms, to Massachusetts General Hospital, which is using the technology as part of its circulating tumor cells (CTC) diagnostic system research.
In May, Massachusetts General Hospital (MGH) reported that its oncology unit received a $15 million research grant to help advance research into its CTC-chip system. The CTC-chip tests blood samples for cancer cells. Circulating tumor cells, which can be related to several types of cancer, travel in patients' bloodstreams and can develop tumors where the cells latch on. The cells can be very uncommon. The CTC-chip can identify a single cancer cell, even among a billion normal cells.
Lire l'intégralité de l'article » (Source: Globes)